Enhanced CLL disease progression was observed in IRF4-deficient TCL1 transgenic mice, finding a severe downregulation of genes involved in T cell activation such as MHC molecules and CD80 and CD86 [68]. The gene discussed is IRF4; the disease is B-cell chronic lymphocytic leukemia.